Pay in 4 interest-free payments of $5.67 Learn more
Ships within 48 hours · Estimated delivery Sep 22 - Sep 27
This study is a preclinical proof-of-principle of therapeutic efficacy of NXP800 both in vitro and in vivo, highlighting the relevance of targeting GCN2, and consequently activating the ISR and UPR, to induce apoptosis and inhibit tumor progression in OS
The medication is expected to become available in the U.S
References Haesebrouck, F
FOR RESEARCH AND IDENTIFICATION PURPOSES ONLY
The HT+GSH treatment significantly increased the activities of APX, G-POD, and GR, but had no obvious effect on CAT and SOD activity relative to the HT treatment
US$ 24.45
US$ 24.95
US$ 23.22
US$ 26.29
US$ 21.19
US$ 21.68
US$ 25.35
US$ 22.41
US$ 28.70
US$ 26.04
US$ 23.26
